Holen Sie sich die Stockscreener-App
6.03
0.99%
-0.06
Handel nachbörslich:
6.06
0.03
+0.50%
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Is Recursion Pharmaceuticals Stock a Millionaire Maker? - Yahoo! Voices
When (RXRX) Moves Investors should Listen - Stock Traders Daily
1 Artificial Intelligence (AI) Stock That Could Soar in 2025 - Yahoo Finance
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - The Manila Times
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 0.7%Here's Why - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.6% HigherHere's Why - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap UpTime to Buy? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.4%Time to Sell? - MarketBeat
Recursion Pharmaceuticals registers shares for Tempus Labs - Investing.com India
Recursion Pharmaceuticals registers shares for Tempus Labs By Investing.com - Investing.com UK
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.5%Here's What Happened - MarketBeat
State Street Corp Raises Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.8%Here's What Happened - MarketBeat
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance
Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX) - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.4% HigherShould You Buy? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3%What's Next? - MarketBeat
Interesting RXRX Put And Call Options For January 2025 - Nasdaq
Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials - Insider Monkey
Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.7%Here's Why - MarketBeat
Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers - Insider Monkey
Recursion Pharmaceuticals (NASDAQ:RXRX) Receives Buy Rating from Needham & Company LLC - MarketBeat
10 AI News Investors Probably Missed - Insider Monkey
(RXRX) Trading Report - Stock Traders Daily
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.2%Should You Sell? - MarketBeat
Unpacking the Latest Options Trading Trends in Recursion Pharmaceuticals - Benzinga
What's Going On With Recursion Pharmaceuticals Stock?Recursion Pharmaceuticals (NASDAQ:RXRX) - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 21.5% HigherShould You Buy? - MarketBeat
Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245 (NASDAQ:RXRX) - Seeking Alpha
Charles Schwab Investment Management Inc. Has $12.79 Million Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Fmr LLC Buys 170,810 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Benjamin Edwards Inc. - MarketBeat
Recursion Pharmaceuticals CEO sells $285,600 in stock By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals CEO sells $285,600 in stock - Investing.com India
RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.7%Time to Buy? - MarketBeat
Stock Traders Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9%Should You Sell? - MarketBeat
The Future of Medicine: How AI Is Transforming Healthcare and Stock Markets - Baystreet.ca
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):